May 2026
LSD
What May 2026's 10 new studies found, synthesized from the papers below. All LSD research →
The synthesis
Synthesized from 10 studies in the library · AI-generated, grounded in the abstracts below
Found by searching the library for LSD, lysergic acid diethylamide, lysergide, then ranked by relevance.
Research published in May 2026 indicates that LSD may induce neuroplastic changes—such as reversing aging-related transcriptional programs, enhancing white matter integrity, and prolonging stimulation-induced neural activity—which are associated with antidepressant and pain-relief effects, though these findings come from preclinical and small clinical studies. However, epidemiological data show mixed associations: LSD use is linked to higher insomnia severity in young cannabis users, while psychedelic use is associated with lower migraine odds in male twins, and no effects on authoritarian attitudes were found. The evidence is preliminary, with limited sample sizes and a need for replication and long-term outcome data.
Evidence by study
Direction is which way each study's own result points, not our rating of the study.
What the directions mean
- Supports:
- the study found the intervention worked, or its hypothesis held.
- Opposes:
- it found the opposite, no benefit or a harm.
- No effect:
- no significant difference either way.
- Mixed:
- effects in both directions within the same study.
- Unclear:
- the abstract does not report a direction.
| Study | Design | Sample size | Direction | Finding |
|---|---|---|---|---|
| Lysergic acid diethylamide reverses aging- and neurodegeneration-associated brain transcriptional programs 2026 | cross-species transcriptomic analyses with experimental validation | Supports | Chronic LSD treatment induced gene expression patterns anti-correlated with aging and neurodegeneration programs and counteracted amyloid-β-induced alterations in neurons. | |
| IDENTIFYING THE NEUROPHYSIOLOGICAL MECHANISMS UNDERLYING THE POTENTIAL THERAPEUTIC EFFECTS OF PSYCHEDELIC COMPOUNDS 2026 | dissertation combining receptor pharmacology, genetic analysis, and electrophysiological studies | Supports | All tested psychedelics are 5-HT2A agonists, and psilocin increases firing in prefrontal cortex 5-HT2A neurons via a 5-HT2A- and Gαq-dependent mechanism, while 2-bromo-LSD reduces firing through a different mechanism. | |
| Lysergic acid diethylamide pretreatment prolongs brain-stimulation induced neural activity changes. 2026 | experimental study | Supports | LSD pretreatment before brain stimulation led to larger and longer-lasting changes in neural activity compared to stimulation alone, associated with mTOR pathway activation and perineuronal net alterations. | |
| LSD persistently disrupts affective pain processing. 2026 | experimental study | Supports | A single dose of LSD persistently reduced pain affect in rats by suppressing nociceptive responses in the anterior cingulate cortex, dissociating neural excitability from sensory encoding. | |
| Neuroplastic white matter changes in patients with major depression following lysergic acid diethylamide treatment 2026 | randomized controlled trial | 35 | Supports | LSD-induced increases in white matter fractional anisotropy correlated with improvements in depressive symptoms in MDD patients. |
| Prevalence and Reasons for Microdosing Cannabis, Psilocybin, LSD, and MDMA Among U.S. Adults 2026 | cross-sectional survey | 1523 | Mixed | LSD was microdosed by 4.8% of U.S. adults, primarily for recreational purposes, and microdosing was more common among those with poorer mental health and in less restrictive policy environments. |
| Trip killers: Addressing a critical knowledge gap in psychedelic research. 2026 | review | Unclear | The review identifies candidate abortive agents for terminating adverse psychedelic experiences but notes that no systematic evaluation of such pharmacological interventions currently exists. | |
| Effects of psychedelic use on authoritarian attitudes revisited. 2026 | combination: naturalistic observational study, single-arm study, and randomized controlled trial | No effect | No significant changes in authoritarian attitudes were observed after psychedelic use across the three studies. | |
| Associations between psychedelic use and migraine history in Swedish twins. 2026 | cross-sectional twin study | 50726 | Supports | Psychedelic use was associated with lower odds of migraine history among monozygotic twins, with significant effects in males but not in females. |
| 0408 Insomnia Severity Differences by Psilocybin, LSD, and DMT Use Status Among Young Adult Daily Cannabis Consumers in the Herbal Heart Study 2026 | cross-sectional study | 100 | Mixed | LSD and DMT, but not psilocybin, were associated with moderate-to-severe clinical insomnia among young adult daily cannabis consumers. |
Chronic LSD treatment induced gene expression patterns anti-correlated with aging and neurodegeneration programs and counteracted amyloid-β-induced alterations in neurons.
cross-species transcriptomic analyses with experimental validation
All tested psychedelics are 5-HT2A agonists, and psilocin increases firing in prefrontal cortex 5-HT2A neurons via a 5-HT2A- and Gαq-dependent mechanism, while 2-bromo-LSD reduces firing through a different mechanism.
dissertation combining receptor pharmacology, genetic analysis, and electrophysiological studies
LSD pretreatment before brain stimulation led to larger and longer-lasting changes in neural activity compared to stimulation alone, associated with mTOR pathway activation and perineuronal net alterations.
experimental study
A single dose of LSD persistently reduced pain affect in rats by suppressing nociceptive responses in the anterior cingulate cortex, dissociating neural excitability from sensory encoding.
experimental study
LSD-induced increases in white matter fractional anisotropy correlated with improvements in depressive symptoms in MDD patients.
randomized controlled trial Sample size: 35
LSD was microdosed by 4.8% of U.S. adults, primarily for recreational purposes, and microdosing was more common among those with poorer mental health and in less restrictive policy environments.
cross-sectional survey Sample size: 1523
The review identifies candidate abortive agents for terminating adverse psychedelic experiences but notes that no systematic evaluation of such pharmacological interventions currently exists.
review
No significant changes in authoritarian attitudes were observed after psychedelic use across the three studies.
combination: naturalistic observational study, single-arm study, and randomized controlled trial
Psychedelic use was associated with lower odds of migraine history among monozygotic twins, with significant effects in males but not in females.
cross-sectional twin study Sample size: 50726
LSD and DMT, but not psilocybin, were associated with moderate-to-severe clinical insomnia among young adult daily cannabis consumers.
cross-sectional study Sample size: 100
Points of agreement
- LSD induces neuroplastic changes, including transcriptional reversal of aging programs, enhanced white matter integrity, and prolonged neural activity changes.
- LSD's effects are mediated through 5-HT2A receptor signaling and involve prefrontal cortex circuits.
- LSD shows potential therapeutic effects on depression and pain affect in preclinical and clinical studies.
Conflicts
- LSD is associated with both positive therapeutic outcomes (antidepressant, pain relief) and negative associations (insomnia) in different populations.
- Psychedelic use was associated with lower migraine odds in male twins but not in females, suggesting sex-specific effects.
- No effect on authoritarian attitudes was found, contradicting previous research suggesting psychedelics may decrease authoritarianism.
Gaps
- Durability of LSD-induced neuroplastic changes and clinical outcomes beyond 12 weeks is not established.
- Sample sizes are small in clinical trials and experimental studies, limiting generalizability.
- Dose-response relationships and optimal dosing regimens for therapeutic effects are not fully characterized.
- Long-term safety and potential adverse effects of LSD, especially in vulnerable populations, remain understudied.
- Mechanistic links between molecular changes and clinical outcomes need further validation.